# Test Results: literature/synthesis-across-papers.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/synthesis-across-papers.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am synthesizing literature on antibiotic effects on the gut microbiome for a review section. I have read the following papers and am providing summaries below.

Papers provided:

**Paper 1 Summary:**
Anderson et al. (2023). "Broad-spectrum antibiotics cause rapid and persistent microbiome disruption in healthy adults."
- Study: 30 healthy adults given 7-day amoxicillin course
- Finding: 50% reduction in bacterial diversity within 3 days
- Recovery: Partial recovery by 30 days, but some taxa remained depleted at 90 days
- Notable: Proteobacteria expanded during treatment; Bacteroides recovery was slowest

---
**Paper 2 Summary:**
Martinez & Lee (2022). "Microbiome resilience varies by antibiotic class and host factors."
- Study: Meta-analysis of 12 studies (n=340 total subjects)
- Finding: Macrolides caused less diversity loss than fluoroquinolones
- Recovery: Younger subjects (<40) showed faster recovery (mean 21 days vs 45 days)
- Notable: Prior antibiotic exposure associated with slower recovery

---
**Paper 3 Summary:**
Thompson et al. (2024). "Probiotic co-administration does not prevent antibiotic-induced dysbiosis."
- Study: RCT, 60 subjects, probiotic vs placebo during antibiotic treatment
- Finding: No significant difference in diversity loss between groups
- Recovery: Similar recovery trajectories in both arms
- Notable: Probiotic strains did not engraft during antibiotic treatment

Synthesis focus: What is known about microbiome recovery after antibiotic exposure?

My specific research question: Whether there are interventions that could accelerate microbiome recovery.

Task: Synthesize these papers with respect to what is known about microbiome recovery after antibiotic exposure. Structure your synthesis as follows:

1. **Overview**: One paragraph summarizing the collective state of knowledge across these papers.

2. **Points of Agreement**: What do these papers consistently find or conclude? Be specific about which papers support each point.

3. **Points of Disagreement or Tension**: Where do findings, interpretations, or recommendations conflict? Characterize the nature of the disagreement.

4. **Methodological Comparison**: How do the approaches differ? Consider:
   - Study systems/organisms
   - Sample sizes and designs
   - Analytical techniques
   - Outcome measures

5. **Gaps and Limitations**: What questions remain unaddressed across this literature? What limitations are shared?

6. **Synthesis Statement**: Two to three sentences capturing the bottom line for whether there are interventions that could accelerate microbiome recovery.

Constraints:
- Use ONLY information from the papers I have provided
- Do NOT introduce findings, citations, or context from other sources
- When attributing a claim to a paper, be specific (e.g., "Smith et al. found..." not "studies show...")
- If papers contradict each other, present both positions without resolving the disagreement
- If you cannot determine something from the provided texts, state this explicitly

Output format: Use the numbered structure above. For Points of Agreement and Disagreement, use bullet points with specific paper attributions.
````

## Model Output
````
# Synthesis: Microbiome Recovery After Antibiotic Exposure

---

## 1. Overview

Across the three provided papers, a consistent picture emerges of antibiotic-induced microbiome disruption as a meaningful and not fully reversible phenomenon within typical observation windows, though the degree and duration of disruption vary by antibiotic class and host characteristics. Anderson et al. (2023) and Martinez & Lee (2022) together establish that diversity loss is rapid and that recovery is incomplete or prolonged for at least some individuals and taxa. Thompson et al. (2024) adds a critical intervention-focused dimension, finding that probiotic co-administration — one of the most commonly proposed mitigation strategies — did not meaningfully alter either the disruption or the recovery trajectory. Taken together, these papers characterize microbiome recovery as a slow, variable, and currently difficult-to-accelerate process, while leaving open the question of what, if any, interventions might be effective.

---

## 2. Points of Agreement

- **Antibiotic exposure causes substantial, measurable reductions in microbiome diversity.**
  Anderson et al. documented a 50% reduction in bacterial diversity within 3 days of amoxicillin treatment. Martinez & Lee's meta-analysis confirmed diversity loss across all antibiotic classes examined, though the magnitude varied. Both papers treat diversity loss as a reliable outcome of antibiotic exposure.

- **Recovery is incomplete within short-to-medium follow-up windows.**
  Anderson et al. found that some taxa remained depleted at 90 days post-treatment, with Bacteroides recovery being particularly slow. Martinez & Lee similarly found that recovery timelines extended to 21–45 days depending on host age, implying that full recovery — if it occurs — takes considerable time. Neither paper reports complete restoration of baseline microbiome composition within their observation periods.

- **Recovery is variable across individuals and is shaped by host-level factors.**
  Martinez & Lee specifically identified age and prior antibiotic exposure as factors associated with recovery speed. Anderson et al.'s observation that specific taxa (e.g., Bacteroides) recovered more slowly than others also implies within-individual variability in compositional recovery. Both papers frame recovery as heterogeneous rather than uniform.

- **Probiotic co-administration does not appear to prevent or substantially mitigate antibiotic-induced dysbiosis.**
  Thompson et al. found no significant difference in diversity loss or recovery trajectory between probiotic and placebo groups, and noted that probiotic strains failed to engraft during antibiotic treatment. This finding is not directly contradicted by Anderson et al. or Martinez & Lee, neither of which examined probiotic interventions, making Thompson et al. the sole source on this point — but no paper in this set supports probiotics as effective.

---

## 3. Points of Disagreement or Tension

- **The relative severity of disruption across antibiotic classes is addressed only by Martinez & Lee and cannot be cross-validated.**
  Martinez & Lee (meta-analysis) found that macrolides caused less diversity loss than fluoroquinolones. Anderson et al. studied only amoxicillin (a penicillin-class antibiotic), and Thompson et al. does not specify which antibiotic class was used in their RCT. This means the class-specific finding from Martinez & Lee cannot be confirmed or challenged by the other two papers, and it is unclear whether the recovery dynamics described by Anderson et al. are generalizable to other antibiotic classes.

- **There is an implicit tension regarding the clinical utility of probiotics.**
  Thompson et al.'s finding that probiotics did not accelerate recovery or prevent dysbiosis stands as a direct challenge to any implicit assumption — common in clinical practice — that probiotic co-administration is a useful protective strategy. While neither Anderson et al. nor Martinez & Lee explicitly advocate for probiotics, they also do not address this question. The tension is therefore between Thompson et al.'s null finding and the absence of any supporting evidence for probiotics across this literature, rather than a direct contradiction between papers.

- **The framing of "recovery" is not consistent across papers.**
  Anderson et al. define recovery in terms of specific taxon-level restitution (e.g., Bacteroides, Proteobacteria). Martinez & Lee use mean recovery time as a summary metric, likely reflecting diversity indices given the meta-analytic context. Thompson et al. refer to "diversity loss" and "recovery trajectories" without specifying the exact metric. Because these papers may be measuring recovery differently, their timelines and conclusions are not directly comparable, and it is unclear whether they are describing the same biological phenomenon with the same precision.

---

## 4. Methodological Comparison

| Feature | Anderson et al. (2023) | Martinez & Lee (2022) | Thompson et al. (2024) |
|---|---|---|---|
| **Study design** | Prospective observational cohort | Meta-analysis of 12 studies | Randomized controlled trial (RCT) |
| **Sample size** | n = 30 | n = 340 (pooled) | n = 60 |
| **Population** | Healthy adults | Mixed (12 studies) | Not fully specified in summary |
| **Antibiotic(s)** | Amoxicillin (7-day course) | Multiple classes (macrolides, fluoroquinolones, others) | Not specified in summary |
| **Intervention tested** | None | None | Probiotic vs. placebo |
| **Follow-up duration** | 90 days | Varies by study (21–45 days reported) | Not specified in summary |
| **Primary outcome** | Bacterial diversity; taxon-level composition | Diversity loss; recovery time | Diversity loss; recovery trajectory |

**Key methodological observations:**

- **Anderson et al.** provides the most granular longitudinal data on a single antibiotic, enabling taxon-level tracking over time, but is limited by a small sample (n=30) and a single antibiotic class, restricting generalizability.

- **Martinez & Lee** offers the broadest coverage through meta-analysis and the largest effective sample size (n=340), and is the only paper to examine host-level moderators (age, prior antibiotic exposure) systematically. However, meta-analyses aggregate heterogeneous studies, and the summary provided does not detail how recovery was operationalized consistently across the 12 included studies.

- **Thompson et al.** is the only RCT in this set and the only paper to test an active intervention, giving it the strongest internal validity for its specific question (probiotic efficacy). However, the summary does not specify the antibiotic used, the probiotic strains tested, or the follow-up duration, which limits interpretation of how broadly the null finding applies.

- **No paper in this set** reports on dietary, fecal microbiota transplant, or other non-probiotic interventions. Analytical techniques (e.g., 16S rRNA sequencing vs. shotgun metagenomics) are not specified in any of the provided summaries, making it impossible to assess comparability of diversity metrics across studies.

---

## 5. Gaps and Limitations

**Unaddressed questions across this literature:**

- **No paper examines non-probiotic interventions.** Beyond probiotics (addressed only by Thompson et al.), no paper in this set investigates dietary modification, prebiotic supplementation, fecal microbiota transplantation, or other strategies that might accelerate recovery. The question of whether any intervention can accelerate recovery therefore remains largely open based on these three papers alone.

- **Long-term recovery beyond 90 days is not characterized.** Anderson et al. follow subjects to 90 days and find incomplete recovery; the other papers report shorter or unspecified windows. Whether full recovery eventually occurs — and over what timescale — cannot be determined from these papers.

- **The functional significance of microbiome disruption is not addressed.** All three papers focus on compositional metrics (diversity, taxon abundance). None of the provided summaries report on functional outcomes (e.g., metabolic capacity, immune effects, clinical health outcomes), leaving unclear whether the observed disruptions have measurable consequences for host health.

- **Mechanisms of differential recovery are not explained.** Anderson et al. note that Bacteroides recovery is slowest and that Proteobacteria expand during treatment, but the mechanisms underlying these patterns are not addressed in any paper. Similarly, Martinez & Lee identify age and prior antibiotic exposure as moderators without explaining the biological basis.

- **The probiotic null finding may not generalize across strains or antibiotic classes.** Thompson et al. tested specific (unspecified in the summary) probiotic strains alongside an unspecified antibiotic. Whether different probiotic formulations, dosing regimens, or antibiotic contexts would yield different results cannot be determined from this paper alone.

**Shared limitations:**

- All three studies focus on adults; no paper addresses pediatric populations, the elderly, or immunocompromised individuals.
- The specific microbiome assessment methods are not described in the provided summaries, making cross-study comparability of diversity metrics uncertain.
- None of the papers provided include a no-antibiotic control arm that would allow quantification of natural microbiome fluctuation over the same time periods.

---

## 6. Synthesis Statement

Based on the three papers provided, microbiome recovery after antibiotic exposure is slow, incomplete within typical observation windows, and shaped by host factors such as age and prior antibiotic history (Anderson et al., 2023; Martinez & Lee, 2022). The only intervention directly tested across this literature — probiotic co-administration — did not accelerate recovery or prevent dysbiosis, with probiotic strains failing to engraft during antibiotic treatment (Thompson et al., 2024). Whether other interventions could meaningfully accelerate recovery remains an open question that these papers, taken together, do not address.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers all required sections. Complete, no truncation. Synthesis statement is appropriately hedged ("Whether other interventions could meaningfully accelerate recovery remains an open question"). Strong cross-model agreement.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Spot-check each cited fact against source paper excerpts
- Whether the hedged synthesis framing matches reviewer preference
- That author/year citations are preserved exactly from source

## Overall Assessment
- **Recommendation:** Pass
- **Notes:** Alex Alexiev (2026-06-29): **What still needs human verification:**
- Spot-check each cited fact against source paper excerpts: I'm not finding any of these papers?
- Whether the hedged synthesis framing matches reviewer preference: yes
- That author/year citations are preserved exactly from source: yes but I'm not finding the papers online

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
